Vankomisine Dirençli Enterokoklar (VRE) - EKMUD
Vankomisine Dirençli Enterokoklar (VRE) - EKMUD
Vankomisine Dirençli Enterokoklar (VRE) - EKMUD
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Toplum Kökenli Enfeksiyonlarda Direnç ve Tedavi:<br />
Üriner Sistem Enfeksiyonları<br />
li-related lower urinary tract infections. Int J Antimicrob<br />
Agents 2007;29:62-5.<br />
35. Rodríguez-Baño J, Alcalá JC, Cisneros JM, et al. Community<br />
infections caused by extended-spectrum beta-lactamase-producing<br />
Escherichia coli. Arch Intern Med.<br />
2008;168:1897-902.<br />
36. Rodríguez-Baño J, Navarro MD, Romero L, et al. Epidemiology<br />
and clinical features of infections caused by extended-spectrum<br />
beta-lactamase-producing Escherichia<br />
coli in nonhospitalized patients. J Clin Microbiol<br />
2004;42:1089-94.<br />
37. Rodríguez-Baño J, Navarro MD, Romero L, et al. Riskfactors<br />
for emerging bloodstream infections caused by<br />
extended-spectrum beta-lactamase-producing Escherichia<br />
coli. Clin Microbiol Infect 2008;14:180-3.<br />
38. Rodríguez-Baño J, Navarro MD, Romero L, et al. Community-acquired<br />
bacteraemia due to extended-spectrum<br />
beta-lactamase-producing Escherichia coli: An emerging<br />
clinical challenge. Clin Microbiol Infect<br />
2005;11(Suppl 2):72-3.<br />
39. Romero L, López L, Rodríguez-Baño J, Ramón Hernández<br />
J, Martínez-Martínez L, Pascual A. Long-term study<br />
of the frequency of Escherichia coli and Klebsiella pneumoniae<br />
isolates producing extended-spectrum betalactamases.<br />
Clin Microbiol Infect 2005;11:625-31.<br />
40. Sobel JD, Kaye D. Urinary tract infections. In: Mandell<br />
GL, Bennett JE, Dolin R (eds). Principles and Practice of<br />
Infectious Diseases. 6 th ed. Philadelphia: Elseiver Inc,<br />
2005:875-905.<br />
26<br />
41. Stamm WE, Hooton TM. The management of urinary<br />
tract infection. N Engl J Med 1993;329:1328-34.<br />
42. Wagenlehner FME, Niemetz A, Dalhoff A, Naber KG.<br />
Spectrum and antibiotic resistance of uropathogens<br />
from hospitalized patients with urinary tract infections:<br />
1994-2000. Int J Antimicrob Agents 2002;19:557-64.<br />
43. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ,<br />
Stamm WE. Guidelines for antimicrobial treatment of<br />
uncomplicated acute bacterial cystitis and acute pyelonephritis<br />
in women. Clin Infect Dis 1999;29:745-58.<br />
44. Yalçı A, Aydemir H, Pişkin N, Türkyılmaz R. Semptomatik<br />
üriner sistem infeksiyonu olan hastalardaki üropatojenler<br />
ve antibiyotik duyarlılık oranları. KLİMİK Derg<br />
2008;21:112-7.<br />
45. Yılmaz N, Ağuş N, Öner Ö, Akgüre N. Yatan ve ayaktan<br />
hastalardan izole edilen üropatojen Escherichia coli kökenlerinin<br />
antibiyotik direnç oranları. 2. <strong>EKMUD</strong> Kongresi<br />
2008 Kongre Özet Kitabı. Poster No: 49, s: 205.<br />
46. Yilmaz E, Akalin H, Ozbey S, et al. Risk factors in community-acquired/onset<br />
urinary tract infections due to<br />
extended-spectrum beta-lactamase-producing Escherichia<br />
coli and Klebsiella pneumoniae. J Chemother<br />
2008;20:581-5.<br />
47. Zhanel GG, Karlowsky JA, Harding GKM, et al. A Canadian<br />
national surveillance study of urinary tract isolates<br />
from outpatients: Comparison of the activities of trimethoprim<br />
sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin,<br />
and ciprofloxacin. Antimicrob Agents Chemother<br />
2000;44:1089-92.<br />
2. Türkiye <strong>EKMUD</strong> Bilimsel Platformu 2009
Change language